Cargando…
Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
Autores principales: | Harding, M. J., Cantwell, B. M., Milstead, R. A., Harris, A. L., Kaye, S. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246458/ https://www.ncbi.nlm.nih.gov/pubmed/3408648 |
Ejemplares similares
-
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
por: Cantwell, B. M., et al.
Publicado: (1988) -
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
por: Jodrell, D. I., et al.
Publicado: (1991) -
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.
por: Curtin, N. J., et al.
Publicado: (1986) -
Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy.
por: Newell, D. R., et al.
Publicado: (1990) -
Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.
por: Ermens, A. A., et al.
Publicado: (1988)